1487P Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results. - Wang, Q.; Xu, A.; Ma, C.; Wang, T.; Liu, P.; Duan, Y.; Kong, T.; Chen, G.; Jia, X.; Shang, K.; Yang, G.; Zhang, G.; et al. (Annals of Oncology, 2023)